Clinical Trial Update: KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing KD019 to erlotinib in advanced non-small cell lung cancer after prior therapy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• KD019

Snippet

Sponsor: Kadmon Corporation, LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED